EUROoC comprises a collection of innovative research projects addressing the development of advanced OoC systems with higher physiological significance going beyond current in vitro testing. The EUROoC project will create advanced OoCs, which closely recapitulate properties of the respective organ tissues in vivo regarding cell types, microenvironment, organ-specific tissue structure and function as well as concepts for the interconnection of individual OoCs.
The various OoC models to be developed comprise heart-on-a-chip, bone-on-a-chip, retina-on-a-chip, lung-on-a-chip, adipose- on-a-chip, guton-a-chip to liver-on-a-chip. The OoC systems will be able to monitor and analyse tissue functionality and response in situ by integrating various novel sensing elements. The OoCs developed will be tested with the regulatory partners through in vitro-in vivo correlations.
Parallelisable microfluidic Heart-on-a-chip systems with integrated sensing capability to monitor maturation and functionality of cardiac microtissues
Application and quantification of mechanical load to a 3D bone-tissue analogue within a microfluidic device – bone-on-a-chip
Development of a microphysiological system that integrates and differentiates tissue-specific ECs
Development of a microfludic-based OoC model as a device for modelling cellular therapy approaches
Gut-on-a-chip modelling microbiome dysbiosis
Retina-on-Chip with Local Oxygen Sensing
Development of an acute lung infection model
Microfluidic methods for bead-based assays on-chip
Development of defined matrices for next-generation OoC systems
Microvasculature-on-a-chip modelling degenerative vascular disease
Establishment of a liver zonation and infection model
Integration of on-chip TEER measurement and of iPSC-derived epithelial cells in the HuMiX gut/microbiome model
Human immunocompetent WAT-Liver-on-a-chip system with integrated sensors
Optical sensor systems for multi-parametric monitoring and control of OoCs
Optical sensor concepts for monitoring metabolic activity
Information will follow soon.